Skip to main content
Erschienen in: Journal of Interventional Cardiac Electrophysiology 1/2016

03.03.2016

Measuring quality in electrophysiology

verfasst von: Daniel J. Friedman, Sana M. Al-Khatib

Erschienen in: Journal of Interventional Cardiac Electrophysiology | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

The evolving healthcare environment demands optimally measured quality of care. Performance measures are increasingly being used for quality improvement, public reporting, and reimbursement determinations. The National Quality Forum has created rigorous criteria for the evaluation of potential performance measures across medical fields. The Heart Rhythm Society has championed the development of four separate electrophysiology (EP)-specific performance measures: implantable cardioverter defibrillator complication rate, cardiac tamponade and/or pericardiocentesis following atrial fibrillation ablation, infection within 180 days of a cardiac implantable electronic device implantation, replacement, or revision, and in-person evaluation following a cardiac implantable electronic device implantation. National registries serve a key role in developing performance measures and facilitating quality improvement, particularly as they provide improved granularity and accuracy of data compared with administrative claims data. All performance measures demand continued reassessment as technology and performance gaps change and as unintended consequences may arise.
Literatur
4.
Zurück zum Zitat Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators (1991). The New England Journal of Medicine, 325(5), 293–302. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators (1991). The New England Journal of Medicine, 325(5), 293–302.
5.
Zurück zum Zitat Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) (1999). Lancet, 353(9169), 2001–2007. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) (1999). Lancet, 353(9169), 2001–2007.
6.
Zurück zum Zitat Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors (1992). The New England Journal of Medicine, 327(10), 685–691. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors (1992). The New England Journal of Medicine, 327(10), 685–691.
7.
Zurück zum Zitat Packer, M., Bristow, M. R., Cohn, J. N., Colucci, W. S., Fowler, M. B., Gilbert, E. M., et al. (1996). The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. carvedilol heart failure study group. The New England Journal of Medicine, 334(21), 1349–1355.CrossRefPubMed Packer, M., Bristow, M. R., Cohn, J. N., Colucci, W. S., Fowler, M. B., Gilbert, E. M., et al. (1996). The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. carvedilol heart failure study group. The New England Journal of Medicine, 334(21), 1349–1355.CrossRefPubMed
10.
Zurück zum Zitat Dodson, J. A., Reynolds, M. R., Bao, H., Al-Khatib, S. M., Peterson, E. D., Kremers, M. S., et al. (2014). Developing a risk model for in-hospital adverse events following implantable cardioverter-defibrillator implantation: a report from the NCDR (National Cardiovascular Data Registry). Journal of the American College of Cardiology, 63(8), 788–796.CrossRefPubMed Dodson, J. A., Reynolds, M. R., Bao, H., Al-Khatib, S. M., Peterson, E. D., Kremers, M. S., et al. (2014). Developing a risk model for in-hospital adverse events following implantable cardioverter-defibrillator implantation: a report from the NCDR (National Cardiovascular Data Registry). Journal of the American College of Cardiology, 63(8), 788–796.CrossRefPubMed
11.
Zurück zum Zitat Prutkin, J. M., Reynolds, M. R., Bao, H., Curtis, J. P., Al-Khatib, S. M., Aggarwal, S., et al. (2014). Rates of and factors associated with infection in 200 909 Medicare implantable cardioverter-defibrillator implants: results from the national cardiovascular data registry. Circulation, 130(13), 1037–1043.CrossRefPubMed Prutkin, J. M., Reynolds, M. R., Bao, H., Curtis, J. P., Al-Khatib, S. M., Aggarwal, S., et al. (2014). Rates of and factors associated with infection in 200 909 Medicare implantable cardioverter-defibrillator implants: results from the national cardiovascular data registry. Circulation, 130(13), 1037–1043.CrossRefPubMed
12.
Zurück zum Zitat Lewis, W. R., Piccini, J. P., Turakhia, M. P., Curtis, A. B., Fang, M., Suter, R. E., et al. (2014). Get with the guidelines AFIB: novel quality improvement registry for hospitalized patients with atrial fibrillation. Circulation. Cardiovascular Quality and Outcomes, 7(5), 770–777.CrossRefPubMed Lewis, W. R., Piccini, J. P., Turakhia, M. P., Curtis, A. B., Fang, M., Suter, R. E., et al. (2014). Get with the guidelines AFIB: novel quality improvement registry for hospitalized patients with atrial fibrillation. Circulation. Cardiovascular Quality and Outcomes, 7(5), 770–777.CrossRefPubMed
14.
Zurück zum Zitat Krumholz, H. M., Herrin, J., Miller, L. E., Drye, E. E., Ling, S. M., Han, L. F., et al. (2011). Improvements in door-to-balloon time in the United States, 2005 to 2010. Circulation, 124(9), 1038–1045.CrossRefPubMedPubMedCentral Krumholz, H. M., Herrin, J., Miller, L. E., Drye, E. E., Ling, S. M., Han, L. F., et al. (2011). Improvements in door-to-balloon time in the United States, 2005 to 2010. Circulation, 124(9), 1038–1045.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat McCabe, J. M., Kennedy, K. F., Eisenhauer, A. C., Waldman, H. M., Mort, E. A., Pomerantsev, E., et al. (2014). Reporting trends and outcomes in ST-segment-elevation myocardial infarction national hospital quality assessment programs. Circulation, 129(2), 194–202.CrossRefPubMed McCabe, J. M., Kennedy, K. F., Eisenhauer, A. C., Waldman, H. M., Mort, E. A., Pomerantsev, E., et al. (2014). Reporting trends and outcomes in ST-segment-elevation myocardial infarction national hospital quality assessment programs. Circulation, 129(2), 194–202.CrossRefPubMed
16.
Zurück zum Zitat Wimmer, N. J., Cohen, D. J., Wasfy, J. H., Rathore, S. S., Mauri, L., & Yeh, R. W. (2014). Delay in reperfusion with transradial percutaneous coronary intervention for ST-elevation myocardial infarction: Might some delays be acceptable? American Heart Journal, 168(1), 103–109.CrossRefPubMedPubMedCentral Wimmer, N. J., Cohen, D. J., Wasfy, J. H., Rathore, S. S., Mauri, L., & Yeh, R. W. (2014). Delay in reperfusion with transradial percutaneous coronary intervention for ST-elevation myocardial infarction: Might some delays be acceptable? American Heart Journal, 168(1), 103–109.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Gasparini, M., Proclemer, A., Klersy, C., Kloppe, A., Lunati, M., Ferrer, J. B., et al. (2013). Effect of long-detection interval vs standard-detection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial. JAMA, 309(18), 1903–1911.CrossRefPubMed Gasparini, M., Proclemer, A., Klersy, C., Kloppe, A., Lunati, M., Ferrer, J. B., et al. (2013). Effect of long-detection interval vs standard-detection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial. JAMA, 309(18), 1903–1911.CrossRefPubMed
18.
Zurück zum Zitat Moss, A. J., Schuger, C., Beck, C. A., Brown, M. W., Cannom, D. S., Daubert, J. P., et al. (2012). Reduction in inappropriate therapy and mortality through ICD programming. The New England Journal of Medicine, 367(24), 2275–2283.CrossRefPubMed Moss, A. J., Schuger, C., Beck, C. A., Brown, M. W., Cannom, D. S., Daubert, J. P., et al. (2012). Reduction in inappropriate therapy and mortality through ICD programming. The New England Journal of Medicine, 367(24), 2275–2283.CrossRefPubMed
19.
Zurück zum Zitat Varma, N., Piccini, J. P., Snell, J., Fischer, A., Dalal, N., & Mittal, S. (2015). The relationship between level of adherence to automatic wireless remote monitoring and survival in pacemaker and defibrillator patients. Journal of the American College of Cardiology, 65(24), 2601–2610.CrossRefPubMed Varma, N., Piccini, J. P., Snell, J., Fischer, A., Dalal, N., & Mittal, S. (2015). The relationship between level of adherence to automatic wireless remote monitoring and survival in pacemaker and defibrillator patients. Journal of the American College of Cardiology, 65(24), 2601–2610.CrossRefPubMed
20.
Zurück zum Zitat Saxon, L. A., Hayes, D. L., Gilliam, F. R., Heidenreich, P. A., Day, J., Seth, M., et al. (2010). Long-term outcome after ICD and CRT implantation and influence of remote device follow-up: the ALTITUDE survival study. Circulation, 122(23), 2359–2367.CrossRefPubMed Saxon, L. A., Hayes, D. L., Gilliam, F. R., Heidenreich, P. A., Day, J., Seth, M., et al. (2010). Long-term outcome after ICD and CRT implantation and influence of remote device follow-up: the ALTITUDE survival study. Circulation, 122(23), 2359–2367.CrossRefPubMed
21.
Zurück zum Zitat Slotwiner, D., Varma, N., Akar, J. G., Annas, G., Beardsall, M., Fogel, R. I., et al. (2015). HRS Expert Consensus Statement on remote interrogation and monitoring for cardiovascular implantable electronic devices. Heart Rhythm, 12(7), e69–e100.CrossRefPubMed Slotwiner, D., Varma, N., Akar, J. G., Annas, G., Beardsall, M., Fogel, R. I., et al. (2015). HRS Expert Consensus Statement on remote interrogation and monitoring for cardiovascular implantable electronic devices. Heart Rhythm, 12(7), e69–e100.CrossRefPubMed
22.
Zurück zum Zitat Wilkoff, B. L., Fauchier, L., Stiles, M. K., Morillo, C. A., Al-Khatib, S. M., Almendral, J., et al. (2016). 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Heart Rhythm, 13(2), e50–86. doi:10.1016/j.hrthm.2015.11.018. Wilkoff, B. L., Fauchier, L., Stiles, M. K., Morillo, C. A., Al-Khatib, S. M., Almendral, J., et al. (2016). 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Heart Rhythm, 13(2), e50–86. doi:10.​1016/​j.​hrthm.​2015.​11.​018.
Metadaten
Titel
Measuring quality in electrophysiology
verfasst von
Daniel J. Friedman
Sana M. Al-Khatib
Publikationsdatum
03.03.2016
Verlag
Springer US
Erschienen in
Journal of Interventional Cardiac Electrophysiology / Ausgabe 1/2016
Print ISSN: 1383-875X
Elektronische ISSN: 1572-8595
DOI
https://doi.org/10.1007/s10840-016-0118-5

Weitere Artikel der Ausgabe 1/2016

Journal of Interventional Cardiac Electrophysiology 1/2016 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.